APOL1高风险基因型与绝经后非裔美国女性射血分数保留心衰的关联
中位随访11.0年后,高风险携带者(12.3%)的HFpEF住院风险显著增加58%(HR 1.58,95%CI 1.03-2.41),但校正基线eGFR后关联减弱且不再显著(HR 1.50,95%CI 0.98-2.30)。未见与冠心病、卒中或死亡的关联。
要点
- APOL1高风险基因型与HFpEF住院风险增加相关,部分由基线肾功能介导。
- 未发现APOL1高风险基因型与冠心病、卒中或死亡相关。
- 在绝经后非裔美国女性中,APOL1高风险携带者高血压和eGFR降低更常见。
核心结论
- APOL1高风险基因型携带与绝经后非裔美国女性HFpEF住院风险增加相关,部分由基线肾功能解释。
- 未支持APOL1高风险基因型与冠心病、卒中或死亡的关联。
研究设计与样本
- APOL1变异通过基因分型或全外显子组测序推断。
主要发现
- 高风险APOL1携带者(n=1370,12.3%)高血压患病率、降脂药使用比例更高,eGFR更低。
- 平均随访11.0年,高风险携带者HFpEF住院发生率高于低风险携带者,其他结局无差异。
- 校正模型中,高风险携带者HFpEF住院风险增加58%(HR 1.58,95%CI 1.03-2.41)。
- 校正基线eGFR后,HFpEF关联减弱且不再显著(HR 1.50,95%CI 0.98-2.30)。
临床怎么用
- 对绝经后非裔美国女性,APOL1高风险基因型可提示HFpEF风险增加,尤其需关注基线肾功能。
- 不推荐基于APOL1基因型评估冠心病、卒中或死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: APOL1 genotypes are associated with kidney diseases in African American individuals and may influence cardiovascular disease and mortality risk, but findings have been inconsistent. OBJECTIVE: To discern whether high-risk APOL1 genotypes are associated with cardiovascular disease and stroke in postmenopausal African American women, who are at high risk for these outcomes. DESIGN, SETTING, AND PARTICIPANTS: The Women's Health Initiative is a prospective cohort that enrolled 161 838 postmenopausal women into clinical trials and an observational study between 1993 and 1998. This study includes 11 137 African American women participants who had a clinical event from enrollment to June 2014. Data analyses were completed from January 2017 to August 2017. EXPOSURES: The variants of APOL1 were genotyped or imputed from whole-exome sequencing. MAIN OUTCOMES AND MEASURES: Incident coronary heart disease, stroke and heart failure subtypes, and overall and cause-specific mortality were adjudicated from hospital records and death certificates. Estimated incidence rates were determined for each outcome and hazard ratios (HR) and 95% CIs for the associations of APOL1 groups with outcomes. RESULTS: The mean (SD) age of participants was 61.7 (7.1) years. Carriers of high-risk APOL1 variants (n = 1370; 12.3%) had higher prevalence of hypertension, use of cholesterol-lowering medications, and reduced estimated glomerular filtration rate (eGFR). After a mean (SD) of 11.0 (3.6) years, carriers of high-risk APOL1 variants had a higher incidence rate of hospitalized heart failure with preserved ejection fraction (HFpEF) than low-risk carriers did but showed no differences for other outcomes. In adjusted models, there was a significant 58% increased hazard of hospitalized HFpEF (HR, 1.58 [95% CI, 1.03-2.41]) among carriers of high-risk APOL1 variants compared with carriers of low-risk APOL1 variants. The association with HFpEF was attenuated (HR = 1.50 [95% CI, 0.98-2.30]) and no longer significant when adjusting for baseline eGFR. CONCLUSIONS AND RELEVANCE: Status as a carrier of a high-risk APOL1 genotype was associated with HFpEF hospitalization among postmenopausal women, which is partly accounted for by baseline kidney function. These findings do not support an association of high-risk APOL1 genotypes with coronary heart disease, stroke, or mortality in postmenopausal African American women.
引用
- Franceschini N, Kopp JB, Barac A, et al. Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women. JAMA Cardiol. 2018. PMID: 29971324. doi:10.1001/jamacardio.2018.1827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。